Elekta (EKTA) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
27 Dec, 2025Executive summary
Net sales increased by 2% in constant currencies to SEK 4,695M, driven by strong performance in Europe and APAC, while the US and China declined.
Order growth accelerated in Q3, with a book-to-bill ratio of 1.15, supported by new product launches (Elekta Evo and Elekta ONE) and commercial wins in Mexico, the US, and Europe.
Adjusted gross margin improved to 37.1% due to price increases and favorable product mix, especially from services.
Adjusted EBIT margin rose to 11.7% year-over-year, supported by gross margin gains and higher amortization from new product launches.
Record high cash flow after investments reached SEK 730M in Q3, supported by improved EBITDA and working capital reduction.
Financial highlights
Net income reached SEK 336M; EPS was SEK 0.89, up from SEK 0.80 last year, and adjusted EPS reached SEK 0.94.
Service business grew 10% year-over-year, while solution sales declined by 4% due to lower US and China volumes.
Rolling 12-month cash flow from operating activities was SEK 2.38B, with cash conversion at 79%.
Cost reduction initiatives delivered SEK 264M in annual run rate savings, ahead of plan.
Cash and equivalents rose to SEK 3,583M, mainly due to a SEK 1,500M bond issue for future refinancing.
Outlook and guidance
Full-year 2024-25 net sales expected to be broadly stable; EBIT margin to be lower than 2023-24 due to continued weakness in the US and China.
Targeting EBIT margin of 14% or higher beyond 2024-25, driven by product portfolio and demand.
Near-term caution due to lower volumes in the US and China; positive long-term outlook based on innovation and backlog.
Latest events from Elekta
- Adjusted gross margin rose to 38.3% as restructuring costs and FX reduced net income.EKTA
Q3 20265 Mar 2026 - SEK 500m+ savings, job cuts, and innovation drive target growth in China and US.EKTA
Strategy update2 Feb 2026 - Sales up 5% year-over-year, but Q4 declined; margin recovery expected in H2 2024/25.EKTA
Q4 23/2431 Jan 2026 - Net sales up 1% with strong U.S. growth and a major Mexico order; margin recovery expected.EKTA
Q1 24/2523 Jan 2026 - Sales and margins declined, but new products and cost savings are set to boost performance.EKTA
Q2 24/2512 Jan 2026 - AI-driven adaptive radiotherapy and software boost growth, margins, and global adoption.EKTA
Investor update10 Jan 2026 - Margins improved, cash flow strengthened, and major cost-saving actions launched.EKTA
Q2 25/2626 Nov 2025 - Net sales up 3% in constant currency, margins down, net income up 50%, cash flow improved.EKTA
Q1 25/2623 Nov 2025 - Margin expansion, software growth, and profitable orders drive confidence in mid-term targets.EKTA
Investor update21 Nov 2025